Research is being conducted on the prevalence and outcomes of HER2-low status in early-stage HER2-negative breast cancer. Some studies suggest that HER2-low status may be linked to worse survival rates in certain breast cancer subtypes, while others explore the clinical characteristics and prognostic impact of HER2-low expression. The relationship between HER2-low status and breast cancer outcomes is still being investigated, with various studies examining its implications in different contexts.